Xconomy | Boston - Business + Technology in the Exponential Economy

No Appeal for Boston Scientific, No Luck for CombinatoRx Drug, No Complaints From Harvard, & More Boston-Area Life Sciences News
Takeda Hands $20M Over to Alnylam, Skyhook Helps Mozilla Find its Way, Nuance Nabs Nokia Agreement, & More Boston-Area Deals News
Another Big Venture Round for Acceleron Pharma
Alnylam and Merck Go Their Separate Ways, TransMedics Files to Go Public, ZipCar Reservation System Ready to Go Anywhere, and More
Turbine Confirms $40M Round, Nuance Prices Secondary Offering, Sirtris Completes GSK Deal, & More Deals News

Clarus Leads $60M Biolex Deal

Cambridge, MA-based Clarus Ventures led a $60 million Series D financing for Biolex Therapeutics, according to an announcement from the Pittsboro, NC-based startup. The deal was joined by new investor OrbiMed Advisors and existing investors including Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corporation, Investor Growth Capital, Polaris Ventures, Mitsui & Company, The Dow Chemical Company, JP Morgan Securities, and the North Carolina Economic Development Fund. Biolex plans to use the cash to ready its lead drug candidate, a controlled-release version of interferon alfa for the treatment of hepatitis C, for Phase 3 clinical trials.

Comments | Permalink |